COVID-19 has a major impact on all medical disciplines, among them hepatology. The new vaccines have potential to finally solve this global health crisis. This webinar will dive into different issues related to COVID-19 vaccination including the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations (e.g. old age), the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases.
The scientific rationale for currently recommended vaccination strategies concerning patients with liver diseases will also be discussed, as well as the first outcome data of population-based vaccination in patients with and without liver diseases.
The webinar will take place on 9 March, from 18:00 to 19:30 CET
|18:00-18:02||Welcome & Introduction
Ulrich Beuers, Amsterdam University Medical Centers
Verena Keitel, Universitätsklinikum Düsseldorf
|18:02-18:17||Defining liver patients in urgent need of a COVID-19 vaccine for priorisation
Thomas Marjot, University of Oxford, United Kingdom
|18:17-18:32||Overview over the COVID-19 vaccines available in Europe
Julian Schulze-zur-Wiesch, University Medical Center Hamburg-Eppendorf, Germany
|18:32-18:47||Benefit/risk of COVID-19 vaccinations: what do we know to date and how can it translate to specific populations?
Miriam Sturkenboom, Julius Center Research Program Cardiovascular Epidemiology, Utrecht, Netherlands
|18:47-19:02||First practical experiences with COVID-19 vaccination in Israeli patients with liver disease
Rifaat Safadi, Hadassah Medical Centers of the Hebrew, University Jerusalem, Israel
|19:02-19:30||Discussion and Q&A
- Hepatologists, gastroenterologists
- General practitioners
- Health care professionals
- Clinical scientists
- Basic scientists